Download or read book Research Development of the European Pharmaceutical Industry written by Arne Noack and published by GRIN Verlag. This book was released on 2007-11 with total page 54 pages. Available in PDF, EPUB and Kindle. Book excerpt: Seminar paper from the year 2003 in the subject Business economics - Operations Research, grade: A, Vrije University Brussel (Vesalius College), course: Economics, language: English, abstract: The health of their population has always been a great concern for governments of Post-War Europe. In order to achieve their goals they had to work closely together with the pharmaceutical Industry. With the phenomenon of the aging population the importance of development of new drugs is increasing. The increasingly old population of Europe creates a big market for pharmaceutical companies. The pharmaceutical Industry is a very complex sector with close links to other Industries. The chemical Industry for example is an important supplier for materials needed in the process of creating new drugs. Furthermore is the market for pharmaceuticals characterized by extremely little concentration and a huge variety of products. Globally in 1998, the 300 best-selling products held a share of less than 45% of the worlds market. The top two products held 1.3% of the market each.1 This fact creates a necessity for the companies to research new, so called "Blockbuster drugs" to succeed on this market with a high competition. The data on the various methods of drug discovery is enormous and sophisticated. In this paper the structure of the Research & Development sector of the European pharmaceutical industry will be examined, which is of increasing importance for the success of the individual companies. The specific data on the R & D section will be given a general character. Furthermore it will give a brief overview of the different regions in Europe and their individual differences. In the end, the difficulties and challenges of R & D in the pharmaceutical industry will be described and compared to other pharma markets abroad. [1 Data taken from "Combining discovery with development" by Dr. Peter Eddershaw; World pharmaceutical frontiers 2003/2004 ]
Download or read book The Changing Economics of Medical Technology written by Institute of Medicine and published by National Academies Press. This book was released on 1991-02-01 with total page 225 pages. Available in PDF, EPUB and Kindle. Book excerpt: Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Download or read book Research and Development in the Pharmaceutical Industry A CBO Study written by Congressional Budget Office and published by Lulu.com. This book was released on 2013-06-09 with total page 65 pages. Available in PDF, EPUB and Kindle. Book excerpt: Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
Download or read book European Pharmaceutical Research and Development written by and published by . This book was released on 2021 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: With a focus on research and development in the area of innovative medicines, this study discusses a new European approach to pharmaceutical policy. After examining the European pharmaceutical sector's features, and the strengths and weaknesses of the current research and business model, the study explores the need for and the concept of a European infrastructure with a long-term transboundary mission. Any such European medicines infrastructure should focus on threats and areas of research and development that are underinvested under the current business model. More specifically, the study uses an extensive literature review and a targeted survey of international experts from science, industry, public health and government institutions, to investigate the feasibility of different options in terms of the scope of the mission, and legal, organisational and financial arrangements for establishing such a European infrastructure. On the basis of their research, the authors present a range of policy options. The most ambitious of these considers a Europe-wide public infrastructure equipped with budgetary autonomy and home-grown research and development capacity. This organisation would be tasked with building a portfolio of new medicines and related biomedical technologies up to the delivery stage, over the course of 30 years, in partnership with third-party research centres at national or European level and with companies. It would be the most important global player in biomedical innovation in the world.
Download or read book Impact of Big Pharma Organizational Structure on R D Productivity written by Sebastian Held and published by BoD – Books on Demand. This book was released on 2009 with total page 162 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book International Trade and Finance Pharmaceutical Industry in Germany written by Miriam Mennen and published by GRIN Verlag. This book was released on 2010-03-23 with total page 61 pages. Available in PDF, EPUB and Kindle. Book excerpt: Essay from the year 2006 in the subject Pharmicology, grade: 71 % - A, University of Sunderland (Faculty of Business and Law), course: International Trade and Finance, language: English, abstract: This paper will firstly analyse the importance of R&D, its global dimension and its future trends. Furthermore, the emphasis by nations put on investment in knowledge will be explained. The second part then outlines the main economic theories concerning innovation and knowledge creation. Finally, Germany and its pharmaceutical industry will be taken as an example to illustrate the dimensions of investment in R&D and its outcomes.
Download or read book Changing Innovation in the Pharmaceutical Industry written by Andre Jungmittag and published by Springer Science & Business Media. This book was released on 2013-04-17 with total page 195 pages. Available in PDF, EPUB and Kindle. Book excerpt: The internationalization of research and technology is one key component of the globalization of trade and business, with potentially major impacts on patterns of economic development and public policies worldwide. Although certain aspects of this internationalization trend are well documented, and some effects can be quantified, the overall processes are extremely complex and the outcomes are highly uncertain. The existence of the phenomenon is generally accepted, but its importance and the trends are currently the topic of a lively debate. This study on "New Ways in Drug Development in Pharmaceuticals" is part of a three year project which aims at investigating how new concepts of industrial knowledge creation are implemented in the different environ ments of the innovation systems of the United States and Germany. The main focus of the overall project is a series of case studies of innovation practice in different national and sectoral contexts. The following sectors and technological fields are investigated: pharmaceuticals and new ways in drug development by the Fraunhofer Institute for Systems and Innovation Research (ISI), advanced materials by the University Hohenheim, Insti tute of International Management and Innovation (Alexander Gerybadze), financial services and home banking by the Massachusetts Institute of Tech nology (MIT), Center for Industrial Performance (Richard Lester) and the Sloan School of Management (Edward Roberts). Financially the project was supported by the German-American Academic Council, the German Federal Minstry of Education, Science Research and Technology and the Fraunhofer Society.
Download or read book Leading Pharmaceutical Innovation written by Oliver Gassmann and published by Springer Science & Business Media. This book was released on 2008-02-19 with total page 194 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Download or read book Incentives for Research Development and Innovation in Pharmaceuticals written by Walter A. Garcia-Fontes and published by Springer Science & Business Media. This book was released on 2012-01-12 with total page 105 pages. Available in PDF, EPUB and Kindle. Book excerpt: Incentives for innovation are particularly relevant in the pharmaceutical industry where not all social needs provide equally profitable opportunities and where most OECD countries try to implement different measures that promote research in these less profitable areas. This book describes how incentives can be provided to deal with less profitable activities when no clear markets exist for the innovations. The book discusses alternative mechanisms to substitute for inexistent markets, situations where traditional instruments have proven totally insufficient, and the clear mismatch between the size of the markets being targeted and the incentives being provided. Patents become an ineffective way to incentivise R&D when the appropriability is low; this book provides alternative ideas such as allowing for a period of data exclusivity to firms that develop new drugs.
Download or read book A Prospective Analysis of European Pharmaceutical Research Development and Innovation written by and published by . This book was released on 1997 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Ways to Successful Strategies in Drug Research and Development written by H.-Harald Sedlacek and published by John Wiley & Sons. This book was released on 2008-09-26 with total page 278 pages. Available in PDF, EPUB and Kindle. Book excerpt: Strategic planning is a critical subject, central to the success of any scientific and economical enterprise. Not only is the scientific knowledge of many persons needed, but also an assessment of what may occur in the future - which approach may be competitive, which option can be achieved, and how can this be accomplished. With a focus on the various ethical obligations to patients, animals and the environment, this book offers hands-on help on how to develop successful R&D strategies, taking special account of the needs of scientists and managers in the pharmaceutical industry. Key topics include: - evaluation and selection of projects - measures to reduce risks - project management - corporate and technology strategy - managing for innovation The reader will learn the methods needed to elaborate strategies so that he or she will become aware of the numerous managerial, organizational, social and political parameters and forces, the consideration of which is essential for the successful realization of a formulated strategy.
Download or read book The European Pharmaceutical Industry and the Development of Biotechnology written by European Federation of Pharmaceutical Industries' Associations and published by . This book was released on 1984 with total page 36 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book A Prospective Analysis of European Pharmaceutical Research Development and Innovation written by and published by . This book was released on 1997 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book European Pharmaceutical Market Report 1967 written by S. A. Mann and published by . This book was released on 1967 with total page 130 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book The European Pharmaceutical Industry in a Global Economy written by and published by . This book was released on 2014 with total page 58 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Modern Methods of Clinical Investigation written by Institute of Medicine and published by National Academies Press. This book was released on 1990-02-01 with total page 241 pages. Available in PDF, EPUB and Kindle. Book excerpt: The very rapid pace of advances in biomedical research promises us a wide range of new drugs, medical devices, and clinical procedures. The extent to which these discoveries will benefit the public, however, depends in large part on the methods we choose for developing and testing them. Modern Methods of Clinical Investigation focuses on strategies for clinical evaluation and their role in uncovering the actual benefits and risks of medical innovation. Essays explore differences in our current systems for evaluating drugs, medical devices, and clinical procedures; health insurance databases as a tool for assessing treatment outcomes; the role of the medical profession, the Food and Drug Administration, and industry in stimulating the use of evaluative methods; and more. This book will be of special interest to policymakers, regulators, executives in the medical industry, clinical researchers, and physicians.
Download or read book Reuse of Health Data by the European Pharmaceutical Industry written by Lucy Hocking and published by . This book was released on 2019 with total page 83 pages. Available in PDF, EPUB and Kindle. Book excerpt: The health data landscape is rapidly evolving, with a growing recognition within the pharmaceutical industry of the potential benefits of reusing health data for secondary analysis. A new study by RAND Europe, comissioned by the European Federation of Pharmaceutical Industries and Associations, explored current practices in relation to this. The study found that health data is reused across the research and development pathway for a variety of reasons, with the most frequently reused data being electronic health records, health registry data and clinical trial data. Researchers also identified several barriers and enablers to reusing health data, highlighting a number of priority topics which could help to create a more sustainable ecosystem in which health data is reused effectively. These included the need for continued research and development on analytic tools and promoting the adoption of standards and interoperability across datasets, to building public confidence and trust in the pharmaceutical industry to reuse health data and greater collaboration between industry and other key stakeholders.